CN102596247B - 新蛋白 - Google Patents

新蛋白 Download PDF

Info

Publication number
CN102596247B
CN102596247B CN201080044688.3A CN201080044688A CN102596247B CN 102596247 B CN102596247 B CN 102596247B CN 201080044688 A CN201080044688 A CN 201080044688A CN 102596247 B CN102596247 B CN 102596247B
Authority
CN
China
Prior art keywords
seq
antibody
prt5
prt7
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080044688.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102596247A (zh
Inventor
塔玛拉·桑德勒
奥利·德瓦瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Two To Biotech Ltd
Original Assignee
Two To Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Two To Biotech Ltd filed Critical Two To Biotech Ltd
Publication of CN102596247A publication Critical patent/CN102596247A/zh
Application granted granted Critical
Publication of CN102596247B publication Critical patent/CN102596247B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
CN201080044688.3A 2009-08-02 2010-08-02 新蛋白 Expired - Fee Related CN102596247B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL200202A IL200202A0 (en) 2009-08-02 2009-08-02 Novel proteins
IL200202 2009-08-02
PCT/IL2010/000621 WO2011016026A2 (en) 2009-08-02 2010-08-02 Novel proteins

Publications (2)

Publication Number Publication Date
CN102596247A CN102596247A (zh) 2012-07-18
CN102596247B true CN102596247B (zh) 2014-08-06

Family

ID=42263570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080044688.3A Expired - Fee Related CN102596247B (zh) 2009-08-02 2010-08-02 新蛋白

Country Status (11)

Country Link
US (1) US8647632B2 (cg-RX-API-DMAC7.html)
EP (2) EP2461829B1 (cg-RX-API-DMAC7.html)
JP (3) JP2013500739A (cg-RX-API-DMAC7.html)
KR (1) KR101623355B1 (cg-RX-API-DMAC7.html)
CN (1) CN102596247B (cg-RX-API-DMAC7.html)
AU (1) AU2010280368B2 (cg-RX-API-DMAC7.html)
CA (1) CA2769001C (cg-RX-API-DMAC7.html)
IL (3) IL200202A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00879A (cg-RX-API-DMAC7.html)
SG (2) SG178097A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011016026A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742061A4 (en) * 2011-08-08 2015-05-27 Two To Biotech Ltd NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND USES THEREOF IN METHODS FOR THE TREATMENT OF METABOLIC, CARDIAC AND IMMUNE DISORDERS
CN105916874A (zh) * 2014-01-02 2016-08-31 两合生物科技有限公司 新型多肽
CN104262468B (zh) * 2014-09-28 2017-01-18 新乡医学院 一种葡萄糖转运蛋白抑制多肽及其制备方法、应用
TWI604888B (zh) 2015-03-05 2017-11-11 積水特殊化學美國有限責任公司 用於氯乙烯單體(vcm)聚合之聚乙烯醇(pvoh)分散劑
KR102713301B1 (ko) 2015-12-11 2024-10-02 고쿠리츠다이가쿠호진 고치다이가쿠 췌장암 및 췌장관 내 유두상 점액성 종양의 마커

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5286846A (en) 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU2001261513A1 (en) * 2000-05-15 2001-11-26 Braswell, Glenn A. Composition and method for increasing testosterone levels
US6566333B2 (en) 2000-06-19 2003-05-20 Uab Research Foundation Osteoclast secreted chemokine and uses thereof
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2006042002A2 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20080248134A1 (en) 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Expression of human hepatic glucokinase in transgenic mice liver results in decreased glucose levels and reduced body weight;Hariharan N et al.;《Diabetes》;19970131;第46卷(第1期);11-16 *
Molecular cloning and characterization of chemokine-like factor 1(CKLF1),a novel human cytokine with unique structure and potential chemotactic activity;Han W et al.;《Biochemical journal》;20011231;第357卷(第1期);127-135 *

Also Published As

Publication number Publication date
AU2010280368A1 (en) 2012-03-15
AU2010280368B2 (en) 2015-07-23
IL240134A0 (en) 2015-09-24
EP2461829B1 (en) 2016-01-06
JP2013500739A (ja) 2013-01-10
EP2985035A1 (en) 2016-02-17
HK1171672A1 (zh) 2013-04-05
CN102596247A (zh) 2012-07-18
IN2012DN00879A (cg-RX-API-DMAC7.html) 2015-07-10
SG10201404735VA (en) 2014-10-30
US20120121602A1 (en) 2012-05-17
IL200202A0 (en) 2010-05-31
JP5833780B2 (ja) 2015-12-16
IL217758A0 (en) 2012-03-29
CA2769001A1 (en) 2011-02-10
WO2011016026A3 (en) 2011-05-26
EP2461829A2 (en) 2012-06-13
KR20120063474A (ko) 2012-06-15
IL217758A (en) 2015-10-29
KR101623355B1 (ko) 2016-05-23
SG178097A1 (en) 2012-03-29
EP2461829A4 (en) 2013-06-19
CA2769001C (en) 2016-07-26
US8647632B2 (en) 2014-02-11
WO2011016026A2 (en) 2011-02-10
JP2015212302A (ja) 2015-11-26
IL240134A (en) 2016-07-31
JP2015157811A (ja) 2015-09-03

Similar Documents

Publication Publication Date Title
JP6502851B2 (ja) 炎症性状態の予防、処置、および診断のための方法および化合物
JP4917207B2 (ja) 前立腺疾患の検出に有用な試薬及び方法
JP2006523085A (ja) アセチル化タンパク質
JP5833780B2 (ja) 新規タンパク質
JPH06502916A (ja) 糖尿病自己抗体の検出方法
EP2318039B1 (en) Goodpasture antigen binding protein and its detection
US9150642B2 (en) Anti-KTPAF50 antibodies and their uses in therapeutic and diagnostic methods
CN101282989A (zh) 用于诊断风湿性疾病的方法
JP4314386B2 (ja) Bcl−2調節因子(BMF)配列及びアポトーシスの調節におけるそれらの使用
US9296786B2 (en) Shortened secreted polypeptides
JP2005524053A (ja) 乳房の疾患を検出するために有用な試薬及び方法
US20050048490A1 (en) Proteins associated with cell growth, differentiation, and death
JP2003530109A (ja) エルビンをコードする遺伝子及びその診断及び治療的使用
HK1171672B (en) Novel proteins
WO2008066483A1 (en) Use of nalp5 in methods for diagnosis and therapy of parathyroid related disorders
JP2001508297A (ja) ヒトエンドスルフィン遺伝子
JPWO2005056597A1 (ja) 免疫グロブリンFc受容体タンパク質
KR20000075624A (ko) 세포 표면 단백질에 대한 백신의 제조 방법
JP2001215227A (ja) Rcas1の免疫学的測定方法及び測定用キット、抗rcas1抗体の免疫学的測定方法及び測定用キット、並びにrcas1受容体の免疫学的測定方法
JP2001518794A (ja) ヒトgtp結合タンパク質
Cutress BAG-1 expression and function in breast cancer
JPH04364463A (ja) PTHrPのサンドイッチ法による免疫学的測定法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140806

Termination date: 20190802

CF01 Termination of patent right due to non-payment of annual fee